Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Goal Attainment Scaling Record: 2021 – A Year in Review

Curator: Aviva Lev-Ari, PhD, RN, Founder, 1.0 & 2.0 LPBI Group

STRATEGIC MISSIONS

Mission #1: Medical Text Analysis using NLP, ML-AI

Wolfram Vendor selection

Workflow Ten-steps Template for NLP in Books

NLP – Book Assignment

– Genomics Volume 1: Satwik – Started on 1/4/2022

– Genomics Volume 2: Madison – DONE

– Cancer Volume 1: Satwick – NLP – DONE

– Danielle – Book prep PART B

– Cancer Volume 2: Juliet Wu

– Nitric Oxide: Yash C.

– 3D BioPrinting: Ms. Joshi

Organizational

July 19: Launch of LPBI India

Marketing Communication

• March 2: Podcast with many updates – LPBI is a Very Unique Organization
• DESIGN of CONTENT PROMOTION campaigns: Montero & GTO

Mission #2: Blockchain for Content Monetization and Auction of

(1) Curations as NFT and

(2) Therapeutics Molecules

9/14: Selection of Fluree Foundation for our Blockchain

1. IT & Data Science Internship – LPBI gained the code to run Article Views by any date, 2012 – 2021 – Contributions by Srini and by Abhisar
2. Text to Sound: 150 of the 270 Interviews with Scientific Leaders were converted to Podcasts – Contribution by Ethan
3. Sign up agreement with SpeechKit – Text to Sound conversion for (a) $204 for 360 podcasts per year (b) Archive bulk conversion 20 cents per Podcast (c) Use API for Spanish Text to Spanish Sound
4. ALL 18 BOOKS have a COVER PAGE and an eTOCs in Spanish – Montero competed its Contract and was paid by a Loan Aviva made to LPBI.  On 9/1/2021 wired the funds to cover the Invoice.

• DESIGN and ENABLEMENT of Content Monetization – Blockchain
• IT & Data Science – Audit capabilities to Journal Articles

Mission #3: New Genre Scientific Books

1/4/2022 UPDATE

2.0 LPBI Group News

PART A: Spanish Audio

and Bi-lingual Text for eTOCs

PART B: NLP

PART C: Editorials Audio

BUSINESS SIDE

GUEST SPEAKERS:

2/9/2021: Prof. James Jordan, CMU

Discussion on SPACs:

One Possible Strategy for an Acquisition is via a Special Purpose Acquisition Company (SPAC)

3/9/2021:

– I_del_C, MONTERO-LS, Madrid, Spain

– MvR, MD, Helsinki, Finland

– DaveS, CMAA, Medworld Advisors

4/6/2021:

– Dan Halpern on Mercantile Banks

5/11/2021:

– Olivier Jarry, Atlas Advisors, NY, NY

– Mr. Bahl, Mr. Gamota, Mr. Halpern

– Dr. Ofer, Dr. Williams, Dr. Pearlman

6/8/2021: Montero & GTO Presentations

Mission #4: Drug Design with Synthetic Biology Software

• LPBI strategy is for BLOCKCHAIN technology to be MARRIED to NLP FOR CONTENT MONETIZATION
• BLOCKCHAIN for Auction of New molecules:

1. Give Dr. Nir Right of Use
2. Hosting the molecules in Blockchain Knowledge Graph Data Base
3. Open up the molecules for licensing in a cyber secured confidential Auction
4. Host molecules inventories from Technology Transfer Offices in several Academic centers around the Globe. We have relations to three Academic institutions in Israel, and three in the US

8/10: Spanish Translation going on

11/14: Erich of Blockchain Schema

12/14: Xavier and Eric on NFT as Presented by LPBI Group’s Portfolio of IP Assets Classes I – XIV

Portfolio of IP Assets

SCIENCE SIDE

GUEST SPEAKERS:

1/12/2021:

Prof. Martin Schiller

2/9/2021:

Prof. A. Gupta on Ramatroban

– Prof. S. Yedgar

– Dr. Raphael Nir

– Dr. Yigal Blum

Amor18 – ACC

3/9/2021:

– Dr. Tetz & Dr. Kogan

– Prof. A. Gupta on Ramatroban

– Prof. S. Yedgar

4/6/2021:

– Dr. Tetz & Dr. Kogan

– Prof. A. Gupta on Ramatroban

– Prof. S. Yedgar

5/11/2021:

– Discussion on Content sharing with Linguamatics

6/8/2021: Ramatroban

Rehearsal of Linguamatics Proposal for a Health Care Insurer

8/10: Synthetic Biology Software – New Molecules DESIGN

10/12: Dr. Williams presented

• Wolfram Platform: What can LPBI do to get access for MULTIPLE computers beyond 2 seats, currently held by Madison and by Yash – WHAT can we do with Wolfram to enable access to all INTERNS?
• What is the state of development for the decision on the Software to be selected for Synthetic Biology for our Interns?
• HOW the work by David MacMillan on BioCatalysis can be harnessed for our Synthetic Biology for Drug Discovery effort

11/9: PROTAC – PRossetaC with Prof. Nir London, Weizmann Institute